denbinobin: antineoplastic from Dendrobium moniliforme (Orchidaceae); structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Dendrobium moniliforme | species | [no description available] | Orchidaceae | A plant family of the order Asparagales. All members of the orchid family have the same bilaterally symmetrical flower structure, with three sepals, but the flowers vary greatly in color and shape.[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 10423984 |
| CHEMBL ID | 400925 |
| SCHEMBL ID | 1010300 |
| MeSH ID | M0401207 |
| Synonym |
|---|
| CHEMBL400925 |
| denbinobin |
| SCHEMBL1010300 |
| 82526-36-1 |
| 5-hydroxy-3,7-dimethoxyphenanthrene-1,4-dione |
| DTXSID001318428 |
Denbinobin is a novel, naturally occurring phenathroquinone isolated from orchids of the genus Dendrobium. It has remarkable anti-cancer activities demonstrated both in vitro and in vivo.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Denbinobin is a phenanthraquinone derivative present in the stems of Ephemerantha lonchophylla. " | ( Denbinobin induces apoptosis by apoptosis-inducing factor releasing and DNA damage in human colorectal cancer HCT-116 cells. Chen, CC; Chen, TH; Guh, JH; Huang, YT; Pai, HC; Pan, SL; Teng, CM, 2008) | 3.23 |
| "Denbinobin is a novel, naturally occurring phenathroquinone isolated from orchids of the genus Dendrobium that has remarkable anti-cancer activities demonstrated both in vitro and in vivo." | ( Escaping immune surveillance in cancer: is denbinobin the panacea? Magwere, T, 2009) | 1.34 |
| "Denbinobin, which is a phenanthraquinone derivative present in the stems of Ephemerantha lonchophylla, has been demonstrated to display antitumor activity. " | ( The inhibition of angiogenesis and tumor growth by denbinobin is associated with the blocking of insulin-like growth factor-1 receptor signaling. Chen, CC; Lai, CY; Pan, SL; Shen, CC; Teng, CM; Tsai, AC; Wang, CY, 2011) | 2.06 |
Denbinobin treatment also caused DNA damage and activation of the p53 tumor suppressor gene. The denbinobin-treated group showed a significant reduction in tumor metastasis, orthrotopic tumor volume, and spleen enlargement compared to the control group.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Denbinobin treatment also caused DNA damage, activation of the p53 tumor suppressor gene, and upregulation of numerous downstream effectors (p21WAF1/CIP1, Bax, PUMA, and NOXA)." | ( Denbinobin induces apoptosis by apoptosis-inducing factor releasing and DNA damage in human colorectal cancer HCT-116 cells. Chen, CC; Chen, TH; Guh, JH; Huang, YT; Pai, HC; Pan, SL; Teng, CM, 2008) | 2.51 |
| "The denbinobin-treated group showed a significant reduction in tumor metastasis, orthrotopic tumor volume, and spleen enlargement compared to the control group." | ( Denbinobin suppresses breast cancer metastasis through the inhibition of Src-mediated signaling pathways. Chen, CC; Chen, PH; Pai, HC; Peng, CY; Teng, CM; Yang, CR, 2011) | 2.29 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID357348 | Cytotoxicity against mouse RAW264.7 cells assessed as LDH release | 2001 | Journal of natural products, Aug, Volume: 64, Issue:8 | Two phenanthraquinones from Dendrobium moniliforme. |
| AID357353 | Inhibition of secretagogue-induced beta-glucuronidase release in rat neutrophils at 30 uM treated 30 mins before secretagogue challenge measured after 15 mins | 2001 | Journal of natural products, Aug, Volume: 64, Issue:8 | Two phenanthraquinones from Dendrobium moniliforme. |
| AID357346 | Antiinflammatory activity in mouse N9 cells assessed as inhibition of LPS and IFN-gamma-induced nitrite formation at 3 uM treated 1 hr before LPS and IFN-gamma challenge measured after 24 hrs by Griess reaction | 2001 | Journal of natural products, Aug, Volume: 64, Issue:8 | Two phenanthraquinones from Dendrobium moniliforme. |
| AID357350 | Inhibition of secretagogue-induced histamine release in Sprague-Dawley rat peritoneal mast cells at 30 uM treated 30 mins before secretagogue challenge measured after 15 mins | 2001 | Journal of natural products, Aug, Volume: 64, Issue:8 | Two phenanthraquinones from Dendrobium moniliforme. |
| AID312044 | Cytotoxicity against rat hepatocytes at 10 to 100 uM | 2007 | Journal of natural products, Dec, Volume: 70, Issue:12 | Antifibrotic phenanthrenes of Dendrobium nobile stems. |
| AID381193 | Antioxidant activity against copper-induced lipid peroxidation in human LDL after 1 hr relative to probucol | 1999 | Journal of natural products, Sep, Volume: 62, Issue:9 | Antioxidant principles from Ephemerantha lonchophylla. |
| AID357344 | Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha formation at 1 uM treated 1 hr before LPS challenge measured after 24 hrs by ELISA | 2001 | Journal of natural products, Aug, Volume: 64, Issue:8 | Two phenanthraquinones from Dendrobium moniliforme. |
| AID357351 | Inhibition of secretagogue-induced beta-glucuronidase release in Sprague-Dawley rat peritoneal mast cells at 30 uM treated 30 mins before secretagogue challenge measured after 15 mins | 2001 | Journal of natural products, Aug, Volume: 64, Issue:8 | Two phenanthraquinones from Dendrobium moniliforme. |
| AID421897 | Cytotoxicity against human KB cells after 3 days by sulforhodamine B assay | 2009 | Journal of natural products, Feb-27, Volume: 72, Issue:2 | Cytotoxic phenanthrenequinones and 9,10-dihydrophenanthrenes from Calanthe arisanensis. |
| AID357345 | Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced prostaglandin E2 formation at 1 uM treated 1 hr before LPS challenge measured after 24 hrs by EIA | 2001 | Journal of natural products, Aug, Volume: 64, Issue:8 | Two phenanthraquinones from Dendrobium moniliforme. |
| AID357347 | Antiinflammatory activity in mouse N9 cells assessed as inhibition of LPS and IFN-gamma-induced TNFalpha formation at 3 uM treated 1 hr before LPS and IFN-gamma challenge measured after 24 hrs by ELISA | 2001 | Journal of natural products, Aug, Volume: 64, Issue:8 | Two phenanthraquinones from Dendrobium moniliforme. |
| AID357343 | Antiinflammatory activity in mouse RAW264.7 cells assessed as LPS-induced nitrite levels at 1 uM treated 1 hr before LPS challenge measured after 24 hrs by Griess reaction (Rvb=46.6 +/- 0.4) | 2001 | Journal of natural products, Aug, Volume: 64, Issue:8 | Two phenanthraquinones from Dendrobium moniliforme. |
| AID357354 | Inhibition of secretagogue-induced superoxide anion generation in rat neutrophils at 30 uM treated 30 mins before secretagogue challenge measured after 15 mins | 2001 | Journal of natural products, Aug, Volume: 64, Issue:8 | Two phenanthraquinones from Dendrobium moniliforme. |
| AID312043 | Antiproliferative activity against rat HSC-T6 cells after 48 hrs by MTT assay | 2007 | Journal of natural products, Dec, Volume: 70, Issue:12 | Antifibrotic phenanthrenes of Dendrobium nobile stems. |
| AID357352 | Inhibition of secretagogue-induced histamine release in rat neutrophils at 30 uM treated 30 mins before secretagogue challenge measured after 15 mins | 2001 | Journal of natural products, Aug, Volume: 64, Issue:8 | Two phenanthraquinones from Dendrobium moniliforme. |
| AID357349 | Cytotoxicity against mouse N9 cells assessed as LDH release | 2001 | Journal of natural products, Aug, Volume: 64, Issue:8 | Two phenanthraquinones from Dendrobium moniliforme. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.17) | 18.2507 |
| 2000's | 12 (50.00) | 29.6817 |
| 2010's | 11 (45.83) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (19.97) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (4.17%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 23 (95.83%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||